×

Biotech and Pharmaceuticals Pharmaceuticals

  • J&J reveals 3.5% net hike in drug pricing last year

    CNBC's Meg Tirrell reports on a transparency report on drug pricing from drug maker Johnson & Johnson.

  • The latest drugmaker move came Monday, when Johnson& Johnson, the world's biggest maker of health care products, issued its first public report on price increases for its drugs. On Monday, Johnson& Johnson reported that over the past five years, the list price, or retail price, of its drugs rose less than 10 percent each year on average, while the net price, the payment it...

  • Feb 27- U.S. stocks looked set to open slightly lower on Monday as investors paused to assess Wall Street's recent record-setting run. Investors will be closely watching President Donald Trump's address to a joint session of Congress on Tuesday evening for clues on his proposed tax reform and his plans to overhaul the Affordable Healthcare Act.

  • Feb 27- U.S. stock index futures struggled for direction on Monday as investors looked for fresh catalysts following Wall Street's record-setting run. *Investors will keenly watch President Donald Trump's address to a joint session of Congress on Tuesday evening for clues on his proposed tax reform and how he plans to overhaul the Affordable Healthcare Act.

  • *270 mln euros to be invested. PARIS, Feb 27- French drugmaker Sanofi and Swiss manufacturer Lonza will invest 270 million euros in a new large-scale biologics facility that will produce monoclonal antibodies by 2020, the two companies said on Monday. Pending regulatory approvals, the facility- which will be established through a 50-50 joint venture- will be...

  • Brent Saunders, CEO of Botox maker Allergan PLC, last September announced a new "social contract" under which the company would limit annual list price increases for its drugs to below 10 percent. After deducting the discounts insurers and other payers get off the higher list price, Allergan will receive net price increases of around 2 percent to 3 percent on its...

  • Feb 24- Pfizer Inc said it received subpoenas from the U.S. Attorney's Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients. In a regulatory filing on Thursday, Pfizer said the December 2015 and July 2016 subpoenas were related to groups that help cover patient co-payments for...

  • Cramer: What investors need to watch from Buffett next week

    Jim Cramer explains what to listen for from the Oracle of Omaha next week, and key earnings on his radar.

  • Cramer's game plan: Key signals to watch from Warren Buffett

    Jim Cramer explains what to listen for from the Oracle of Omaha next week, and key earnings on his radar.

  • Warren Buffett

    Jim Cramer explains what to listen for from the Oracle of Omaha next week, and key earnings on his radar.

  • Incyte

    Shares of Incyte rose more than 6 percent in Friday trade on news that the pharmaceutical company will join the S&P 500.

  • A heroin user prepares to inject himself in New London, Conn.

    The death rate from drug overdoses more than doubled between 1999 and 2015, according to a report from the CDC.

  • Feb 24- Cempra Inc said on Friday that its oral experimental drug to treat acute bacterial skin infections met the main goal of a late-stage study, sending the company's shares surging about 40 percent in premarket trading. ABSSSI leads to hospitalization of about 5.2 million patients in the United States and Western Europe each year and is often treated with...

  • FRANKFURT, Feb 23- Buyout firm Advent International raised the stakes in a battle for German generic drugs maker Stada Arzneimittel on Thursday with a 3.6 billion euro takeover offer, giving management until Monday to respond. Advent said it offered 58 euros per share, limited until Monday, and made its takeover conditional on receiving an endorsement from...

  • *Advent makes binding 58 euros/ share offer. FRANKFURT, Feb 23- Buyout firm Advent International raised the stakes in the three-way bidding tussle for German drug company Stada Arzneimittel on Thursday with a 3.6 billion euro takeover offer, giving management until Monday to respond. Previous expressions of interest, which have been non-binding, were 56 euros...

  • NEW YORK, Feb 23- A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and kickback scheme. Federal prosecutors accused Gary Tanner, who was a senior director at Canadian drugmaker...

  • Could the border adjustment battle derail tax reform?

    CNBC's Ylan Mui discusses how the Trump administration's planned overhaul of the tax code could impact inversion deals and drug companies.

  • SHANGHAI, Feb 23- China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world's second-largest drug market where many new drugs have been kept out of patients' reach because of high costs. High drug costs and a lack of access to the most recent treatments is a major flashpoint in China, where...

  • COPENHAGEN, Feb 22- Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson& Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters. So that means $13 billion potential if it would work in all the indications, Jan van de Winkel said on Wednesday.

  • BMY clearly 'attractive' takeover target: Pro

    Barbara Ryan, Barbara Ryan Advisors, talks about Carl Icahn's stake in Bristol-Myers and other possible big pharma deals in 2017.